pyoderma gangrenosum
Information
- Disease name
- pyoderma gangrenosum
- Disease ID
- DOID:8553
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03311464 | Completed | Phase 3 | A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan | October 27, 2017 | April 21, 2020 |
| NCT03971643 | Completed | Phase 2 | Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum | May 16, 2019 | January 3, 2022 |
| NCT02733094 | Completed | Phase 1/Phase 2 | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | April 2016 | September 19, 2019 |
| NCT03137160 | Completed | Phase 2 | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | May 4, 2017 | August 16, 2018 |
| NCT00791557 | Completed | N/A | Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease | October 2008 | February 2010 |
| NCT01302795 | Completed | Phase 2 | Canakinumab for Pyoderma Gangrenosum | February 2011 | November 2015 |
| NCT01882504 | Completed | Phase 2 | Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum | May 2013 | October 2015 |
| NCT01965613 | Completed | Phase 2 | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | January 31, 2014 | December 31, 2016 |
| NCT04895566 | Completed | Early Phase 1 | Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma | May 24, 2021 | March 16, 2023 |
| NCT05984654 | Not yet recruiting | N/A | Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum | May 28, 2024 | June 30, 2025 |
| NCT05343754 | Not yet recruiting | Phase 3 | Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum | August 2022 | December 2026 |
| NCT05821374 | Not yet recruiting | Early Phase 1 | Deucravacitinib in PG | March 2025 | January 2026 |
| NCT06092216 | Recruiting | Phase 2 | Spesolimab in Pyoderma Gangrenosum | September 26, 2023 | September 2025 |
| NCT04750213 | Recruiting | A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) | February 12, 2021 | August 31, 2025 | |
| NCT04901325 | Recruiting | Phase 2 | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) | October 2023 | May 31, 2025 |
| NCT05120726 | Recruiting | Phase 4 | A Novel Therapeutic Treatment of Pyoderma Gangrenosum | June 2, 2021 | May 1, 2026 |
| NCT05964413 | Recruiting | Phase 3 | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum | August 15, 2023 | May 15, 2026 |
| NCT03072953 | Terminated | Phase 2 | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum | June 7, 2017 | May 22, 2018 |
| NCT02315417 | Terminated | Phase 3 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | November 2014 | March 2016 |
| NCT02318914 | Terminated | Phase 3 | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum | November 2014 | February 2016 |
| NCT02326740 | Terminated | Phase 3 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | December 2014 | March 2016 |
| NCT01952275 | Unknown status | Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases | January 2014 | January 2020 | |
| NCT04792957 | Unknown status | JAK-STAT Signaling Pathway in Pyoderma Gangrenosum | May 1, 2022 | July 31, 2022 | |
| NCT03636737 | Unknown status | Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum | December 2018 | December 2019 | |
| NCT04274166 | Withdrawn | Phase 2 | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | May 2021 | April 2022 |
| NCT00690846 | Withdrawn | Phase 2 | Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum | July 2007 | July 2007 |
| NCT00730717 | Withdrawn | Phase 2 | Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum | May 2009 | December 2010 |
- Disase is a (Disease Ontology)
- DOID:4223
- Cross Reference ID (Disease Ontology)
- GARD:7510
- Cross Reference ID (Disease Ontology)
- ICD10CM:L88
- Cross Reference ID (Disease Ontology)
- ICD9CM:686.01
- Cross Reference ID (Disease Ontology)
- MESH:D017511
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:74578003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0085652
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0025452
- OrphaNumber from OrphaNet (Orphanet)
- 48104
- MedGen concept unique identifier (MedGen Concept name)
- C0085652
- MedGen unique identifier (MedGen Concept name)
- 43224
- ICD10 preferred id (Insert disease from ICD10)
- D0009964
- ICD10 class code (Insert disease from ICD10)
- L88
- MeSH unique ID (MeSH (Medical Subject Headings))
- D017511